Approval · Notice of Compliance 37932 · 2026
CODEINE CONTIN: Notice of Compliance 37932
Issued July 15, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37932
- Date
- July 15, 2026
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the manufacturing process for the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CODEINE CONTIN | Not yet assigned | — |
Medicinal ingredients
- CODEINE MONOHYDRATE 26.5 MG per TAB
- CODEINE SULFATE TRIHYDRATE 31.4 MG per TAB
- CODEINE MONOHYDRATE 53 MG per TAB
- CODEINE SULFATE TRIHYDRATE 62.7 MG per TAB
- CODEINE MONOHYDRATE 79.5 MG per TAB
- CODEINE SULFATE TRIHYDRATE 94.1 MG per TAB
- CODEINE MONOHYDRATE 106 MG per TAB
- CODEINE SULFATE TRIHYDRATE 125.4 MG per TAB